ArQule to Release Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting

• Published in: Health & Beauty Close - Up
• Format: Newsletter
• Language: English
• Published: Jacksonville Close-Up Media, Inc 19.03.2018
• Subjects: Kinases; Mutation; Ovarian cancer; Trade shows; New York; United States > US; Italy; Ohio; Chicago Illinois

According to a media release, data will be presented in one oral and nine poster sessions on trials conducted by ArQule and its collaborators for BTK inhibitor, ARQ 531, AKT inhibitors, miransertib and ARQ 751, as well as FGFR inhibitor, derazantinib. The oral presentation will highlight data from a phase 1b trial for miransertib in combination with anastrozole in PIK3CA or AKT1-mutant endometrial and ovarian cancers conducted by Dr. David M. Hyman and colleagues at Memorial Sloan Kettering. Oral Presentation Details April 15, Title: A phase 1b study of Miransertib (ARQ 092) in combination with anastrozole in patients with PIK3CA or AKT1-mutant ER+ endometrial and ovarian cancer Time: 3 - 5 p.m. CT Location: Room N427 - McCormick Place North, Level 4 Sponsor: Memorial Sloan Kettering, New York, NY Poster Presentation Details April 15, Title: ARQ 531, a Novel and Reversible Inhibitor of Bruton's Tyrosine Kinase, Displays Favorable Oral Bioavailability and Exposure in patients with B-cell malignancies Time: 1 - 5 p.m. CT Location: Exhibit Hall A, Poster Section 43, Poster Board 18 Sponsor: ArQule, Inc. Title: The novel Bruton's tyrosine kinase inhibitor ARQ 531 disrupts survival signaling and triggers apoptosis in AML cells Time: 1 - 5 p.m. CT Location: Exhibit Hall A, Poster Section 37, Poster Board 3 Sponsor: University of Genoa, Genova, Italy Title: Results of A Phase 1 Dose Escalation Study of ARQ 751 in Adult Subjects with Advanced Solid Tumors with AKT1, 2, 3 Genetic Alterations, Activating PI3K Mutations, PTEN-null, or other known actionable PTEN mutations Time: 1 - 5 p.m. CT Location: Exhibit Hall A, Poster Section 42, Poster Board 17 Sponsor: MD Anderson Cancer Center, Houston, TX April 16, Title: ARQ 531, a potent reversible BTK inhibitor exhibits potent antitumor activity in ibrutinib resistant diffuse large B-cell lymphoma Time: 8 a.m. - 12 p.m. CT Location: Exhibit Hall A, Poster Section 41, Poster Board 8 Sponsor: ArQule, Inc. Title: Preclinical Evaluation of the Tyrosine Kinase Inhibitor ARQ531 in AML Time: 8 a.m. - 12 p.m. CT Location: Exhibit Hall A, Poster Section 38, Poster Board 13 Sponsor: The Ohio State University, Columbus OH Title: In vivo combination of Miransertib (ARQ 092) with anti-PD-1 antibody, Trametinib, Lapatinib, Trastuzumab and Paclitaxel Time: 1 p.m. - 5 p.m. CT Location: Exhibit Hall A, Poster Section 41, Poster Board 23 Sponsor: ArQule, Inc. April 17, Title: Derazantinib (ARQ 087) Pharmacodynamics: Alterations in FGF19/21/23 and phosphate in Patients with Cholangiocarcinoma Time: 8 a.m. - 12 p.m. CT Location: Exhibit Hall A, Poster Section 43, Poster Board 22 Sponsor: ArQule, Inc. Title: In vitro and in vivo effect of ARQ 531 on Trk family kinases Time: 1 p.m. - 5 p.m. CT Location: Exhibit Hall A, Poster Section 36, Poster Board 26 Sponsor: ArQule, Inc. Title: Combinations of imatinib mesylate with AKT inhibitor (Miransertib, ARQ 751) or FGFR inhibitor (Derazantinib) show synergy in GIST cell lines and pre-clinical models Time: 1 p.m. - 5 p.m. CT Location: Exhibit Hall A, Poster Section 37, Poster Board 7 Sponsor: Fox Chase Cancer Center, Philadelphia, PA ((Comments on this story may be sent to newsdesk@closeupmedia.com))